Boston Scientific (BSX) EVP logs major stock awards and tax share withholdings
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Boston Scientific executive Joseph Michael Fitzgerald, EVP & Group President, Cardiology, reported multiple stock-based compensation transactions. He acquired Boston Scientific common stock through exercises of restricted stock units and performance share units, as well as grants totaling 34,898 shares of common stock on February 13, 2026.
On February 13, 14, and 16, 2026, he also had shares of common stock withheld to satisfy tax liabilities, disposing of 33,104, 1,990, and 1,806 shares at $74.73 per share, respectively, as tax-withholding dispositions rather than open-market sales. After these transactions, he directly held 213,907 shares of common stock, and 5,234 additional shares were reported as held indirectly by his child, for which he disclaims beneficial ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
11,119 shares exercised/converted
Mixed
12 txns
Insider
Fitzgerald Joseph Michael
Role
EVP & Group Pres, Cardiology
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 3,960 | $0.00 | -- |
| Exercise | Common Stock | 3,960 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,806 | $74.73 | $135K |
| Exercise | Restricted Stock Units | 4,362 | $0.00 | -- |
| Exercise | Common Stock | 4,362 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,990 | $74.73 | $149K |
| Exercise | Restricted Stock Units | 2,797 | $0.00 | -- |
| Grant/Award | Common Stock | 34,898 | $0.00 | -- |
| Grant/Award | Common Stock | 34,898 | $0.00 | -- |
| Exercise | Common Stock | 2,797 | $0.00 | -- |
| Tax Withholding | Common Stock | 33,104 | $74.73 | $2.47M |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Common Stock — 215,713 shares (Direct);
Common Stock — 5,234 shares (Indirect, By Child)
Footnotes (1)
- On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
FAQ
What did Boston Scientific (BSX) executive Joseph Michael Fitzgerald report in this Form 4?
Joseph Michael Fitzgerald reported stock-based compensation activity, including grants and exercises of restricted and performance share units, plus related tax-withholding share dispositions. These transactions reflect equity awards and associated tax settlements rather than open-market purchases or discretionary sales.
Were any of Joseph Michael Fitzgerald’s Boston Scientific (BSX) transactions open-market sales?
The filing describes dispositions coded “F” as payments of tax liabilities by delivering shares, not open-market sales. Shares were withheld at $74.73 per share to satisfy taxes arising from equity award vesting and exercises, which is standard for stock-based compensation.